Osaka, Japan

Hideki Takasu


 

Average Co-Inventor Count = 12.0

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Otsu, JP (1997 - 2012)
  • Osaka, JP (2013 - 2014)

Company Filing History:


Years Active: 1997-2014

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Hideki Takasu

Introduction

Hideki Takasu is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anticancer compounds. With a total of 5 patents to his name, Takasu's work is recognized for its potential impact on cancer treatment.

Latest Patents

Among his latest patents, Takasu has developed di-substituted pyridine derivatives that exhibit excellent antitumor effects. This novel compound is represented by a specific general formula, which includes various structural components designed to enhance its efficacy. Additionally, he has patented a heterocyclic compound along with a pharmaceutical composition that further demonstrates his innovative approach to cancer therapy.

Career Highlights

Takasu is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to advance his research and development efforts. His work is characterized by a commitment to creating effective therapeutic solutions for challenging medical conditions.

Collaborations

Throughout his career, Takasu has collaborated with notable colleagues, including Makoto Sakamoto and Keisuke Miyajima. These partnerships have contributed to the successful development of his innovative compounds.

Conclusion

Hideki Takasu's contributions to the field of pharmaceuticals, particularly in anticancer research, highlight his role as a significant inventor. His ongoing work at Otsuka Pharmaceutical Company, Limited, and his impressive portfolio of patents underscore his dedication to improving cancer treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…